GlassScriptPhysician profile
Alyssa Young
NPI 1285228510
$2,609.35
in general payments reported to CMS, 2019-2025
22 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $180 · 2023: $827 · 2024: $660 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $890.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $387.76 | 2023-2025 | |
| Lilly USA, LLC | $252.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $206.32 | 2023-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.34 | 2021-2024 | Jardiance, Cyltezo, Stiolto Respimat |
| Ucb, INC. | $108.79 | 2024-2025 | Bimzelx, Cimzia |
| Otsuka America Pharmaceutical, INC. | $104.27 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $92.65 | 2023-2025 | Cologuard Collection Kit |
| Cardiovascular Systems INC. | $78.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $73.08 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $46.74 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $33.89 | 2024 | Auvelity |
| Pfizer INC. | $30.31 | 2023-2024 | |
| Corium, LLC | $29.13 | 2023 | Azstarys |
| Phadia US INC. | $27.10 | 2023-2024 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.49 | 2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $19.14 | 2024 | |
| Currax Pharmaceuticals LLC | $17.37 | 2024 | Onzetra Xsail, Contrave |
| Dexcom, INC. | $17.33 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $16.80 | 2024 | |
| Sandoz INC. | $15.35 | 2023 | Hyrimoz |
| Janssen Biotech, INC. | $15.15 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.